The problem with breast cancer's growth engine is that it does not just hit the gas - it studies the brake system, hires a locksmith, and comes back with a grudge. That is the world cyclin-dependent kinase, or CDK, inhibitors enter: a fight over whether cancer cells get to keep dividing like they are late for a heist.
At the center of this story are CDK4 and CDK6, two enzymes that help usher cells from one stage of growth into the next. In healthy tissue, that process has rules. In many breast cancers, especially hormone receptor-positive disease, those rules get treated like a suggestion box. CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib step in and jam the turnstile. No ticket, no entry to the next phase of cell division. Very satisfying. Very rude to the tumor.
And it works. That is the big reason this new review matters. Knudsen and colleagues are not asking whether CDK inhibition belongs in breast cancer anymore. That argument is over. The field has spent the past decade proving the concept, and now the fight has moved to harder questions: who benefits most, how long the benefit lasts, what to do when resistance shows up, and whether these drugs can break out of their current zip code and help in other cancers too [1,2].
The Brakes Work. Cancer Still Cheats.
This is the awkward truth in oncology: a treatment can be a genuine win and still not be enough. CDK4/6 inhibitors transformed care for many patients with hormone receptor-positive, HER2-negative advanced breast cancer, but tumors adapt. Of course they do. Cancer biology rarely sees a locked door without immediately checking the windows.
That is why so much of the recent action is about combinations and second acts. The phase III postMONARCH trial showed that continuing to target this pathway after prior CDK4/6 treatment can still help, at least in the right setting. Abemaciclib plus fulvestrant improved progression-free survival after disease progression on an earlier CDK4/6 inhibitor, which is a polite scientific way of saying the pathway may still be worth attacking even after round one gets messy [3].
Meanwhile, the phase III PATINA trial pushed CDK4/6 inhibition into another neighborhood: hormone receptor-positive, HER2-positive metastatic breast cancer. Adding palbociclib to anti-HER2 therapy and endocrine therapy extended progression-free survival by roughly 15 months. That is not a rounding error. That is a real delay in disease progression, the kind patients and oncologists notice without needing a forest plot tattooed on the wall [4].
Resistance Is Not Magic. It Is Logistics.
A lot of resistance boils down to cancer cells finding alternate routes around the blockade. If CDK4/6 is the main checkpoint, tumors start leaning on partners like CDK2, or on related growth pathways such as PI3K. This is where the review gets especially interesting, because it shows the field acting less like it found a miracle pill and more like it finally understands the enemy's supply lines.
Preclinical work in 2025 showed that adding a selective CDK2 inhibitor could strengthen the effect of CDK4/6 blockade in breast cancer models, including models of resistant disease [5]. Translation: if the tumor keeps sneaking through the side door, researchers are now standing by the side door with a second lock.
Another line of attack focuses on toxicity. Current CDK4/6 drugs can hit the bone marrow hard, especially through CDK6-related effects, leading to neutropenia and other blood-count trouble. Next-generation CDK4-selective inhibitors aim to keep the anti-cancer punch while causing less hematologic chaos. Early preclinical data on atirmociclib suggest that this might be possible [6]. If that holds up clinically, it would be a classic oncology upgrade: same mission, fewer friendly-fire incidents.
The Biomarker Situation Is Still a Bit of a Mess
Everybody wants the clean test that says, "This patient will benefit, this one will not, please stop guessing." Oncology would love that. Oncology also loves being difficult.
Biomarkers for CDK inhibitor response are improving, but they are not yet the tidy, clinic-ready answer people hoped for. Researchers are exploring gene-expression patterns, RB1 pathway status, cyclin E signaling, thymidine kinase activity, and other molecular clues, but patient selection still lags behind the biology [1,2]. We know enough to suspect the right answer is more nuanced than "CDK4/6 for everyone" and less convenient than a single lab value circled in red.
That may be the most important takeaway from this review. CDK inhibition is no longer a one-trick success story in metastatic breast cancer. It is becoming a broader strategy: combine smarter, sequence smarter, pick patients smarter, and design cleaner drugs.
That is how cancer treatment often advances in real life. Not with one cinematic explosion. With trench-by-trench gains. Ugly resistance mechanisms. Incremental wins. Better maps. Better gear. Fewer wasted shots. Science, in other words, doing its stubborn little job.
References
-
Knudsen ES, Witkiewicz AK, Kabraji S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nature Reviews Drug Discovery. 2026. DOI: https://doi.org/10.1038/s41573-026-01431-5
-
Morrison L, Loibl S, Turner NC. The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nature Reviews Clinical Oncology. 2024;21:89-105. DOI: https://doi.org/10.1038/s41571-023-00840-4
-
Kalinsky K, et al. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. Journal of Clinical Oncology. 2025;43:1101-1112. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/ PMID: https://pubmed.ncbi.nlm.nih.gov/39693591/
-
Metzger O, et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2026;394:451-462. DOI: https://doi.org/10.1056/NEJMoa2511218
-
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. npj Breast Cancer. 2025;11:135. DOI: https://doi.org/10.1038/s41523-025-00851-7 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC12675586/
-
Palmer CL, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43(3):464-481.e14. DOI: https://doi.org/10.1016/j.ccell.2025.02.006 PMID: https://pubmed.ncbi.nlm.nih.gov/40068598/
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.